File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Transforming growth factor-β signal transduction in epithelial cells

TitleTransforming growth factor-β signal transduction in epithelial cells
Authors
KeywordsCancer
Cell cycle
MAPK
Ras
Signal transduction
Smad
TGF-β
Issue Date2001
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/pharmthera
Citation
Pharmacology And Therapeutics, 2001, v. 91 n. 1, p. 1-34 How to Cite?
AbstractTransforming growth factor (TGF)-β is a natural and potent growth inhibitor of a variety of cell types, including epithelial, endothelial, and hematopoietic cells. The ability of TGF-β to potently inhibit the growth of many solid tumors of epithelial origin, including breast and colon carcinomas, is of particular interest. However, many solid tumor cells become refractory to the growth inhibitory effects of TGF-β due to defects in TGF-β signaling pathways. In addition, TGF-β may stimulate the invasiveness of tumor cells via the paracrine effects of TGF-β. Accordingly, in order to develop more effective anticancer therapeutics, it is necessary to determine the TGF-β signal transduction pathways underlying the growth inhibitory effects and other cellular effects of TGF-β in normal epithelial cells. Thus far, two primary signaling cascades downstream of the TGF-β receptors have been elucidated, the Sma and mothers against decapentaplegic homologues and the Ras/mitogen-activated protein kinase pathways. The major objective of this review is to summarize TGF-β signaling in epithelial cells, focusing on recent advances involving the Sma and mothers against decapentaplegic homologues and Ras/mitogen-activated protein kinase pathways. This review is particularly timely in that it provides a comprehensive summary of both signal transduction mechanisms and the cell cycle effects of TGF-β. © 2001 Elsevier Science Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/171694
ISSN
2021 Impact Factor: 13.400
2020 SCImago Journal Rankings: 3.461
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYue, Jen_US
dc.contributor.authorMulder, KMen_US
dc.date.accessioned2012-10-30T06:16:24Z-
dc.date.available2012-10-30T06:16:24Z-
dc.date.issued2001en_US
dc.identifier.citationPharmacology And Therapeutics, 2001, v. 91 n. 1, p. 1-34en_US
dc.identifier.issn0163-7258en_US
dc.identifier.urihttp://hdl.handle.net/10722/171694-
dc.description.abstractTransforming growth factor (TGF)-β is a natural and potent growth inhibitor of a variety of cell types, including epithelial, endothelial, and hematopoietic cells. The ability of TGF-β to potently inhibit the growth of many solid tumors of epithelial origin, including breast and colon carcinomas, is of particular interest. However, many solid tumor cells become refractory to the growth inhibitory effects of TGF-β due to defects in TGF-β signaling pathways. In addition, TGF-β may stimulate the invasiveness of tumor cells via the paracrine effects of TGF-β. Accordingly, in order to develop more effective anticancer therapeutics, it is necessary to determine the TGF-β signal transduction pathways underlying the growth inhibitory effects and other cellular effects of TGF-β in normal epithelial cells. Thus far, two primary signaling cascades downstream of the TGF-β receptors have been elucidated, the Sma and mothers against decapentaplegic homologues and the Ras/mitogen-activated protein kinase pathways. The major objective of this review is to summarize TGF-β signaling in epithelial cells, focusing on recent advances involving the Sma and mothers against decapentaplegic homologues and Ras/mitogen-activated protein kinase pathways. This review is particularly timely in that it provides a comprehensive summary of both signal transduction mechanisms and the cell cycle effects of TGF-β. © 2001 Elsevier Science Inc. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/pharmtheraen_US
dc.relation.ispartofPharmacology and Therapeuticsen_US
dc.subjectCancer-
dc.subjectCell cycle-
dc.subjectMAPK-
dc.subjectRas-
dc.subjectSignal transduction-
dc.subjectSmad-
dc.subjectTGF-β-
dc.subject.meshAnimalsen_US
dc.subject.meshBasic Helix-Loop-Helix Leucine Zipper Transcription Factorsen_US
dc.subject.meshCaenorhabditis Elegans Proteinsen_US
dc.subject.meshDna-Binding Proteins - Chemistryen_US
dc.subject.meshEpithelial Cellsen_US
dc.subject.meshHelminth Proteins - Chemistryen_US
dc.subject.meshHumansen_US
dc.subject.meshMitogen-Activated Protein Kinases - Metabolismen_US
dc.subject.meshReceptors, Transforming Growth Factor Beta - Physiologyen_US
dc.subject.meshRepressor Proteinsen_US
dc.subject.meshSignal Transduction - Physiologyen_US
dc.subject.meshTranscription Factorsen_US
dc.subject.meshTransforming Growth Factor Beta - Physiologyen_US
dc.titleTransforming growth factor-β signal transduction in epithelial cellsen_US
dc.typeArticleen_US
dc.identifier.emailYue, J:jyue@hku.hken_US
dc.identifier.authorityYue, J=rp00286en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/S0163-7258(01)00143-7en_US
dc.identifier.pmid11707292-
dc.identifier.scopuseid_2-s2.0-0035156083en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035156083&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume91en_US
dc.identifier.issue1en_US
dc.identifier.spage1en_US
dc.identifier.epage34en_US
dc.identifier.isiWOS:000172288500001-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridYue, J=7101875828en_US
dc.identifier.scopusauthoridMulder, KM=7005187184en_US
dc.identifier.issnl0163-7258-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats